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Introduction 
Cryptogenic   chronic  liver disease   is defined   as  chronic liver disease   
the aetiology of which  is unknown or not discernable  after exhaustive 
investigations. The  etiology   in  5-10 % of  cases with  cirrhosis, despite 
reasonably extensive investigations,  remains unresolved(1) and these would 
qualify for the label. 
        Ever  since   new  causes   of  parenchymal  liver damage were discovered 
the proportion of patients with Cryptogenic cirrhosis has diminished. The newer 
causes include Hepatitis C (1999) and more recently Non Alcoholic 
Steatohepatitis or NASH ( 2001) Even more recently there has been evidence 
that Non Cirrhotic portal hypertension (NCPF) ends in chronic liver failure and 
hepatocellular carcinomas (2). It may turn out that this too might be another 
cause of cryptogenic  Cirrhosis.  
Looking for the aetiology of Chronic Liver Disease or Cirrhosis opens up 
the possibility of the successful use of therapeutic agents with improvement (3), 
stabilization or the delay in progression.  Oral antivirals such as Lamivudine are 
good examples of such “rescue” therapy (4).  Once the stage of Cirrhosis   is 
reached many patients are not intensively studied, except for viral serology, 
because Cirrhosis is seen as the end game and cursory treatment other than  
liver transplantation is seen as worthless.  
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This scenario would change if new agents  are discovered that could halt 
or reverse ongoing liver damage in decompensated Hepatitis C infection, NASH 
or NCPF as they have in Hepatitis B.  This has special relevance to India where 
transplantation is beyond the scope of  most sufferers.  
With these as the undergirding considerations, this study was undertaken 
to investigate covert causes of Cryptogenic Chronic Liver disease.  This was a 
retrospective study and as the issue is complex, we concentrated only on two 
specific areas – 1) Steatohepatitis as a cause of “cryptogenic chronic liver 
disease” and 2) Cryptogenic chronic liver disease with elevated alkaline 
phosphatase levels with special reference to Primary Biliary cirrhosis and the anti 
mitochondrial antibody. 
The first issue has not been examined in previous reports from India as 
biopsies are rarely done in those with near end stage disease. The second issue 
has also not received much attention in India. There are, of course, many other 
causes of “cryptogenic Liver disease” which have not been investigated in this 
study. Others in our group have studied NCPF(5) as mentioned before.  We were 
constrained by other factors from studying causes such as occult HBV infection 
which may have been another treatable cause of liver disease (6).Rarer causes 
such as Iron storage disorders and auto immune liver diseasewere also not 
covered in the current study.  
 
 3
In steatohepatitis, we attempted to answer these two questions 1) Would    
laboratory tests and clinical features aid in arriving at an aetiological diagnosis of   
NASH?( 6, 7) Would the severity of the histological changes  be reflected and 
therefore  be predictable from scores such as the MELD score.. The implications 
of these are as follows. 
The diagnosis of the condition may be made easier if there are specific 
clinical signs  as biopsies of the liver are not widely conducted or possible in 
patients with  decompensation. A concordant scoring system where histology 
matches a MELD score would make therapeutic decision making easier.  
The second part related to the possibility of those patients with chronic 
Liver disease with high serum levels of alkaline phosphatase, actually having 
Primary   Biliary Cirrhosis. The test used for the diagnosis of this condition is the 
antimitochondrial antibody (AMA). The AMA is reported to be more than 90-95% 
sensitive and more than 90-95 % specific(6).  There are about 5% of patients 
who are negative for AMA but have the   other features of PBC(7).   
The first question we asked is how frequently in this study population of 
chronic liver disease with elevated alkaline   phosphatase was this test positive.  
If the test was positive in the majority it would mean that testing need not be 
done as the pre-test possibility would be high.  If on the other   hand the test was 
rarely positive biopsy would need to be done more often. 
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The second query was to find out if the population that tested positive was 
in any way different from those who tested negative. If similar then the 
implications are that the test is falselynegative in the majority of cases. If different 
then the pristine disease is probably very rare in this country. The former 
conclusion can be arrived at only after more intense investigation. 
These two issues may appear to be unrelated but as they are both in the 
realm of chronic liver disease of unknown aetiology they will be presented 
together.                          
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Review of Literature 
There have been some studies on Cryptogenic liver disease, Cirrhosis is 
usually accepted as ‘‘cryptogenic’’ only after an extensive evaluation has 
excluded recognizable etiologies. The prevalence of cryptogenic cirrhosis ranges 
from 5% to30% of cirrhotic patients in past series.(5) Several explanations may 
be offered as possible underlying etiologies include occult alcohol abuse, occult 
viral (non-B, non-C hepatitis, silent autoimmune hepatitis, or progression of 
nonalcoholic steatohepatitis (8).   The prevalence of clinically silent autoimmune 
hepatitis is not known; however, asymptomatic patients with autoimmune 
hepatitis and previously unrecognized cirrhosis have been described (9). Non-B, 
non-C hepatitis is thought to account for about 15% of post transfusion hepatitis 
and may exist in a silent form for years.Obesity and non–insulindependent 
diabetes mellitus are the two most common conditions associated with 
NASH,(10) which is frequently asymptomatic10 and which can progress silently 
to cirrhosis with loss of definitive histological features(11). 
NONALCOHOLIC STEATOHEPATITIS was first proposed in Nonalcoholic 
steatohepatitis (NASH) is the term used to describe the distinct clinical entity in 
which patients lack a history of significant alcohol consumption (≤40gm/d) but 
have liver biopsy findings indistinguishable from alcoholic steatohepatitis(12).  
Other terms that have infrequently been used to describe this condition include 
pseudoalcoholic hepatitis, alcohol-like hepatitis, fatty liver hepatitis, 
steatonecrosis, and diabetic hepatitis.  
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NASH is also considered to be a subset of nonalcoholic fatty liver disease 
(NAFLD).  Diagnosis of NASH was based on the following criteria: (i) intake of 
less than 20 g of ethanol per day, (ii) biopsy proven steatohepatitis; steatosis,  
inflammatory  infiltrates, and  ballooning  degeneration  with or without Mallory  
bodies  or pericellular/perivenular fibrosis, (iii) appropriate exclusion of other liver 
diseases.  
The detection of NASH is usually delayed, since there are no serum 
Surrogate markers for NASH, and a definitive diagnosis requires a liver 
biopsy(13).  The detection of NASH is usually delayed, since there are no serum 
surrogate markers for NASH, and a definitive diagnosis requires a liver 
biopsy(14).  Today, it is considered a nonspecific term encompassing several 
clinicopathologic entities (steatosis alone, steatonecrosis, steatohepatitis and 
histologic alcoholiclike hepatitis) that are similar to alcoholic liver disease. 
Studies of nonalcoholic fatty liver disease have come to conflicting conclusions 
about the course of the disease.  It can be argued that the disparate results are 
largely the result of nonuniform definitions.  When histologic features such as 
hepatocyte  ballooning,  necrosis, and  Mallory hyaline  are seen, nonalcoholic  
fatty  liver  disease has  been shown  to be  associated with an  aggressive  
outcome. Steatosis alone,   in contrast, appears to be benign. The current  
understanding  of nonalcoholic  fatty liver disease, the limited  treatments  
available(15).   
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EPIDEMIOLOGY:  The prevalence of NASH in the general population is 
incompletely understood.   The major risk factors for nonalcoholic fatty liver 
disease (NAFLD),  central obesity, type 2 diabetes mellitus, dyslipidemia, and 
metabolic syndrome are common in western societies. NAFLD is the most 
common liver disorder in Western industrialized countries, affecting 20 to 40 
percent of the general population (16). 
Estimates of current prevalence range from 5 to 30 percent in the Asia-
Pacific region, depending on the population studied(17).   
PATHOGENESIS:  The pathogenesis of nonalcoholic fatty liver disease has not 
been fully elucidated.  The most widely supported theory implicates insulin 
resistance as the key mechanism leading to hepatic steatosis, and perhaps also 
to steatohepatitis.  Othershave proposed that a "second hit," or additional 
oxidative injury, is required tomanifest the necroinflammatory component of 
steatohepatitis. Hepatic iron, leptin, anti-oxidant deficiencies, and intestinal 
bacteria have all been suggested as potential oxidative stressors. 
CLINICAL COURSE AND PROGNOSIS:  Relatively few patients have been 
observed prospectively to document the natural history of NASH. NASH is 
generally considered to be a clinically stable disorder and has a markedly better 
prognosis than alcoholic steatohepatitis. A population-based study in the United 
States found that patients with nonalcoholic fatty liver disease had slightly lower 
overall survival than expected for the general population (standardized mortality 
ratio of 1.34, 95% CI 1.003-1.76)(17) . Higher mortality was associated with 
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advancing age, impaired fasting glucose, and cirrhosis. NASH may be an 
important underlying cause of cryptogenic cirrhosis, particularly among older, 
diabetic women(18).   
Independent predictors of fibrosis progression included diabetes mellitus, 
a low initial fibrosis stage, and a higher body mass index. Elevated liver enzymes 
were also a predictor of progression(19).  Approximately 38 to 50 percent of 
patients with alcoholic hepatitis progress to cirrhosis over a seven-year period 
(20,21); comparable values for NASH are much lower at 8 to 26 percent 
(22,23,24) . NASH is also associated with higher 5- and 10-year survival rates 
than alcoholic hepatitis (67 versus 38 percent and 59 versus 15 percent, 
respectively).  Patients who developed cirrhosis from NASH may also be at 
increased risk for hepatocellular carcinoma (25,26). 
Clinical features and diagnosis: Most patients with NASH are 
asymptomatic although fatigue, malaise, and vague right upper abdominal 
discomfort bring some patients to medical attention(27). The most common 
presentation is elevation of liver aminotransferases detected on routine 
laboratory testing.  Hepatomegaly is a frequent finding.Serum AST and ALT are 
elevated in almost 90 percent of patients. The AST/ALT ratio is usually less than 
1; this is much lower than the ratio in alcoholic hepatitis, which is usually above 2 
and averaged 2.85 in one report and 2.6 in another . Alkaline phosphatase is less 
frequently elevated and hyperbilirubinemia is uncommon (28).   Ultrasonography 
often reveals a hyperechoic texture or a bright liver because of diffuse fatty 
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infiltration(29) . However, this is a nonspecific finding and should not be used to 
make the diagnosis of NAFLD. 
Both CT and MRI can identify steatosis but   are not sufficiently sensitive  
to detect inflammation or fibrosis(30).   
             Liver biopsy is the only way to confirm or exclude the diagnosis of NASH 
(31,32) A histologic scoring system has been proposed that can assist in 
diagnosis of  nonalcoholic fatty liver disease and may be useful for assessing the 
response to therapy(33).  
TREATMENT: There is no proven effective therapy for NASH, although 
modification of risk factors, such as obesity, hyperlipidemia, and poor diabetic 
control is generally recommended.Weight loss and increased physical activity 
can lead to sustained improvement in liver enzymes, histology, serum insulin 
levels, and quality of life(34).  Cryptogenic chronic liver disease  with  elevated  
Alkaline phosphatase.   Possible Primary biliary cirrhosis (PBC) is an uncommon 
condition found throughout the world that primarily affects middle-aged women. 
Most patients  are   identified  in an asymptomatic phase,   but   gradually they 
develop  symptoms  of pruritus,  fatigue,  and symptoms of associated 
syndromes or end-stage liver  disease. 
Typical  laboratory  findings  are  elevations   of alkaline phosphatase   
levels Modest elevations  of  aspartate aminotransferase (AST) and   alanin 
aminotransferase (ALT)  levels, and positive    antimitochondrial   antibody test 
 10
results.  The characteristic   pathologic   features   of PBC   are destruction and 
drop-out of   intrahepatic   bile   ducts, chronic portal tract   inflammation, 
cholestasis,   and   progressive    fibrosis, cirrhosis, and portal hypertension. 
Treatment options include ursodeoxycholic acid (UDCA), cholestyramine, 
replacement of fat-soluble vitamins, management of complications of portal 
hypertension, and liver transplantation for end-stage disease.   
Pathogenesis and Genetics:  The etiology and pathogenesis of PBC are 
unknown.  A variety of etiologies have been   postulated,  including   infectious  
causes; however, the most common view is  that the   disease falls   within   the 
category of autoimmune diseases (35).  
The rationale for this disease is that multiple features of PBC support a 
Primary  autoimmune  pathogenesis,  including  the histologic features of the liver  
bile  duct  lesions;  characteristic  autoantibodies;   strong   female 
predominance; an  association, although   weak,  with MHC  class II genes; the 
frequent association with other autoimmune syndromes. 
AMAs are the most distinctive specific immunologic characteristic of PBC 
and, not surprisingly, have been the focus of numerous studies.  As noted in the 
preceding text, AMAs can inhibit the enzymatic activity of their target antigens in 
vitro; however, it is  not  known  whether  this occurs  in vivo. 
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Autoantibodies may potentially cause tissue injury, regardless of whether 
they alter the function of their target antigen; therefore, this particular issue does 
not resolve the question of the pathogenicity of AMAs.  AMAs do fix complement; 
however, remarkably   little attention has been directed at determining whether 
there is specific deposition of AMAs  at  sites of tissue injury in the liver.     
A number of attempts to induce biliary disease in anima l models have met 
with limited success.  In one study, immunization of mice with PDC-E2 resulted in 
an antibody response, however, without evidence of biliary disease (36).  In other   
model systems,  the presence  of multiple  positive and  negative  genetic 
susceptibility genes is necessary in addition to environmental triggers to produce 
autoimmune  disease(37). 
Considerable information has emerged to define the nature of both the B-
cell and T-cell responses to the autoantigens recognized by AMAs.  There is 
overlap between epitopes recognized by B cells and both CD4+ T cells and 
CD8+ T cells, and there is enrichment for specific antigen-reactive   clones within 
the liver(38) .Cytokines   produced  in liver infiltrates   are  dominated  by  TH1 
cytokines  but also  contain TH2 cytokines,  providing a  mixed picture.  
Furthermore, expression of adhesion molecules and chemokines,   such as 
fractalkine, by biliary epithelial cells provide further details on potential mediators 
involved in the formation of inflammatory lesions within the liver. However, the 
precise sequence of events and specific effector mechanisms contributing to bile  
duct  injury  are as  yet  undefined, and  the possibility  that the inflammatory   
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lesions  are entirely  secondary  in nature   has  not been eliminated.  Other 
animal   models have been examined that might contribute insights into the 
pathogenesis of PBC.  In an interesting example of serendipity, elimination of a 
specific diabetes-determining locus in the nonobese diabetic (NOD) mouse 
eliminates  diabetes but  results  in a mouse with a characteristic spontaneous 
development of a  unique liver  phenotype  consisting of peribiliary infiltrates, 
autoantibodies, and  cystic  biliary  lesions( 39). 
The striking female predominance of PBC obviously links the 
pathogenesis of the disease to the genetic basis of sex determination, as for   
many other autoimmune diseases.  However, the specific causal mechanisms 
are currently unclear. 
One recent population-based study confirmed that autoimmune  
conditions are found in approximately  one  half of  patients  and  that  the  
prevalence of autoimmune disease in first-degree   family  members  is  14% 
(40), consistent with the thesis that PBC shares  common  genetic  susceptibility  
traits  with other autoimmune conditions. 
More recently, an international study evaluated 16 twin pairs with PBC, of 
whom 8 were confirmed  to be monozygotic (41).  
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Table-1: Epidemiology and Genetics- 
                       
      
Autoantibodies: 
Extensive studies have refined diagnostic testing forAMAs, which are 
found in up to 95% of patients (8).  Cloning and characterization of the M2 
autoantigens recognized  by  PBC  sera have led  to the  identification  of four  
major components of a family  of  mitochondrial  antigens  that  contain  lipoic 
acid  and are  members of the 2-oxoacid  dehydrogenase (2-OAD)  multimeric  
enzyme  complexes (42,43,44,45).  These includepyruvate dehydrogenase  
complex  (PDC), 2-oxoglutarate  Dehydrogenase Complex  (OGDC), and 
branched-chain 2-oxoacid  dehydrogenase complex  (BCOADC)(46,47). 
Approximately 95% of sera of patients  with PBC  reacts  with  both the  
PDC core dihydrolipoamide  acetyl  transferase  (E2) structure  and  the  E3-
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binding protein (E3BP) by  immunoblot  or  enzyme-linked  immunosorbent  
assay (ELISA),  these two subunits  being  completely  cross-reactive(48,49,50,).    
PBC sera also react, at a much lower frequency, with other components of PDC, 
including the E1α and   E1β subunits (51). Sera also react with the E2 subunits of 
OGDC and BCOADC with  a  frequency  of 90% and 50%,  respectively. 
Pathology 
   The gross pathologic   features  of  PBC  are  not  specific  for  the  
disease and includebile  staining  of the  liver,  enlargement,  fine nodularity,  
and, eventually, a grossly  cirrhotic  appearance. 
The characteristic   microscopic  hepatic  abnormalities   include  portal 
inflammation with destruction  and  disappearance  of  intrahepatic  bile ducts, 
abnormal bile duct proliferation,  fibrosis,  and cirrhosis. 
In stage 1, Portal lesions are characterized by damage to bile ducts.  The 
duct is  typically surrounded   by a dense  lymphocytic  infiltrate,  which may also 
include  histiocytes,  plasma  cells, eosinophils,  and, occasionally,  true 
epithelioid  giant cells.   
In stage 11 of the disease  is  characterized  by the  appearance  of   abnormal 
proliferating  bile  ductules  without  duct lumens,  disappearance   of normal bile 
ducts,  and  extension  of the  portal  inflammation  into  the  hepatic 
parenchyma. 
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In stage 3, there is a substantial increase in fibrosis, and fibrous septa 
may Link portal tracts.  Lymphocytic infiltrates remain in portal tracts, but bile 
ducts may be difficult to identify or completely absent. 
Stage 4 is characterized by frank cirrhosis with regenerative nodules.   
Clinical Features: 
In order of frequency, the most common symptoms of PBC are fatigue, 
pruritus, and   jaundice. Occasionally, patients have right upper quadrant 
abdominal pain.  Many other symptoms may be present, including that of   
associated syndromes, Such as dry mouth and  eyes,  Raynaud's phenomenon,  
and    arthralgias.   
As the disease progresses,  the most  common   physical   findings  are 
hepatomegaly, splenomegaly, excoriations,  skin hyperpigmentation,  jaundice,  
and xanthelasma (52). 
Occasionally, patients are brought to attention because of xanthoma, 
xanthelasma, increasing skin pigmentation, or fracture.  Much less commonly,  
the presenting  symptoms  may be due to  decompensated liver disease,  
including ascites, edema, bleeding, or encephalopathy. 
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Routine Laboratory Tests: 
The routine laboratory abnormalities in PBC are typical of chronic   
cholestatic Syndromes and chronic liver disease. 
Table -2 
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Complications: 
Table-3 
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THERAPY: 
UDCA is the only U.S. Food and Drug Administration (FDA)-approved 
medical therapy for PBC, which is generally agreed to ameliorate serum 
biochemical abnormalities and potentially delay progression of disease to death 
or need for transplantation, although controversy remains about the utility of the 
drug. A number of mechanisms have been proposed by which UDCA is 
therapeuticin PBC, including anticholestatic effects and anti–apoptotic actions 
(53,54).   
And also  therapies  directed  at  complications,  including  osteoporosis, 
fat-soluble  vitamin   deficiency, and  complications  of portal hypertension, such  
as  ascites,  edema,  variceal  bleeding,  and  hepatic encephalopathy. 
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PART - I 
Studies on Non-Alcoholic Steatohepatitis 
Material and methods 
Study design: 
This was a retrospective case-control analysis. 
Sample size: 
We studied 100 subjects with 50 subjects in each arm. This was an 
arbitrary number and was not based on any calculation because there were no 
previous studies that could be used to determine sample size. 
Subjects: 
This study was conducted in the Department of Gastroenterological 
Sciences, Christian Medical College, Vellore. There were a total of 100 subjects, 
50 subjects were cases and 50 were controls.  
The reports of liver biopsies obtained in the Department between June 
2004 and July 2007 were examined. All sequential cases of those with 
histological evidence of Steatohepatitis were chosen and their records examined. 
Those patients with other  putative  causes like Hepatitis B (this included patients 
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who had a positive IgG anticore antibody), Hepatitis C and alcohol were 
excluded.   This group formed the cases for the study. From the records of the 
same years a further 50 patients were chosen arbitrarily if they had a known 
cause of the disease. Therefore liver biopsy was the basis of the diagnosis in the 
first 50 (i.e. cases) and a definite disease aetiology the basis of choosing the 
second 50 (i.e. controls). 
The next stage was extracting from the records the clinical features and 
investigations of this group (both cases and controls) at the time of that 
admission.  The MELD score at the time of presentation was calculated on all 
subjects. The following steps were undertaken.   
The clinical findings and investigational reports of the cases were 
compared with those in the controls to look for any significant differences.  The 
clinical findings on presentation that were recorded for the study were the 
presence of jaundice , ascites and pedal oedema. Other clinical findings were not 
included in the comparative analysis. Encephalopathy and spontaneous bacterial 
peritonitis was recorded if it was the reason for admission. A past history of either 
was disregarded.  
Among the investigations, the indices of liver function, haematological 
parameters such as haemoglobin and platelets, ESR and Anti nuclear antibody 
(if available) were compared in the two groups. Further the ratio such as 
SGOT/SGPT was also compared. Other investigations such as imaging and  
endoscopy were not included in the study. 
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  Based on the histology reports the cases were classified into those with 
mild, moderate and severe parenchymal disease. A correlation with the MELD 
score was attempted. 
Statistical Methods: 
Descriptive statistics like mean and SD were presented for normally 
distributed continuous variables and median with interquartile  range for non-
normally distributed continuous variables The results between the two groups 
were compared  for statistically significant  difference. For the categorical 
variables chi-square test was used. For continuous variable with normal 
distribution, t- test was used. For continuous variable with non-normal 
distribution, Mann-Whitney’s U test was used.  P value of <0.05 was considered 
significant. The statistical analysis was done using SPSS software for windows 
version 16. 
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Results 
GENDER and AGE: There were 35 males and 15 female in group-1 and 30 
males and 20 females in group-2. There were no significant differences in these 
numbers between patients and controls. The ages of the cases of steatohepatitis 
varied between 7 – 67years  with  mean ±SD=45.1±10.426.The ages  of the 
control group  varied  between 14-62 years with mean ± SD =39.49 ± 31.826. 
Table-4 
Gender Male Female Total 
Group-1(cases) 35(70%) 15(30%) 50(100%) 
Group-2(control) 30(60%) 20(40%) 50(100%) 
 
GENDER: 
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CLINICAL FINDINGS: 
JAUNDICE: 12(24%) patients in gr-1 and 21(42%) patients in Gr-2 were              
jaundiced, so jaundice is more common in the control group as                   
compared to  cases, which is  significant  statistically(P<0.05).   
Table-5      
Jaundice yes No Total 
Group-1(cases) 12(24%) 38(76%) 50(100%) 
Group-2(control) 21(42%) 29(58%) 50(100%) 
                    
JAUNDICE: 
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ASCITES: 10(20%) patients in Group-1 and 21 (42%) patients in                    
Groups-2 had ascites. Ascites is more common in the control group and this 
finding is  statistically significant(P<0.05).   
Table-6 
Ascites yes No Total 
Group-1(cases) 10(20%) 40(80%) 50(100%) 
Group-2(control) 21(42%) 29(58%) 50 (100%) 
 
ASCITES:             
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EDEMA:  16(32%) patients from gr-1 and 5(10%) patients from gr-2 had bilateral 
pedal edema and this difference is statistically significant (P<0.05). 
Table-7 
Edema Yes No Total 
Group-1(cases) 16(32%) 34(68%) 50(100%) 
Group-2(control) 05(10%) 45(90%) 50(100%) 
 
EDEMA: 
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COMPLICATIONS: 
Spontaneous bacterial peritonitis: 1(2%)   patient from Gr-1 and 5(10%)          
patients from Gr-2 had SBP.  The control group  had a higher incidence of          
SBP, but this did not  reach statistical significance. 
Table-8 
SBP Yes No Total 
Group-1(cases) 1(2%) 49(98%) 50(100%) 
Group-2(control) 5(10%) 45(90%) 50(100%) 
       
 SBP: 
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HEPATIC ENCEPHALOPATHY: 5(10%)   patients in gr-1 and 3(06%) patients         
from gr-2 had hepatic encephalopathy. Here, the   incidence of hepatic         
encephalopathy was more in the cases, but again this was not statistically 
significant. 
Table-9 
HE Yes No Total 
Group-1(cases) 05(10%) 45(90%) 50(100%) 
Group-2(control) 03(06%) 44(94%) 50(100%) 
 
Hepatic Encephalopathy: 
 
 
 
 28
BLEED: 3(6%) patients in Gr-1 and 10(20%) patients from Gr-2 had upper g.i. 
bleed, control group more variceal bleed as compared to cases, which is  
significant statistically(P<0.05). 
Table-10 
Bleed Yes No Total 
Group-1(cases) 03(06%) 47(94%) 50(100%) 
Group-2(control) 10(20%) 40(80%) 50(100%) 
 
Gastrointestinal bleed: 
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Composite table 5-10 
Indices Cases(n=50) Control (n=50) Significant 
Jaundice 12(24%) 21(42%) * 
Ascites 10(20%) 21(42%) * 
Edema 16(32%) 05(10%) * 
SBP 01(2%) 05(10%) - 
HE 05(10%) 03(06%) - 
Bleed 03(06%) 10(20%) * 
* Æ statistically Significant (p<0.05) 
SBP= Spontaneous  bacterial peritonitis, HE = Hepatic encephalopathy 
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INVESTIGATIONS AND LABORATORY PARAMETERS: 
These laboratory investigations (ref. Table -11) did not show any 
Significant differences  between cases and control  except  ESR(<0.05). 
T – test: 
Table-11 
              
Group Statistics
50 3.392 .8121 .1149
50 3.256 .8553 .1210
50 4.496 .9337 .1320
50 4.272 .8347 .1180
50 14.514 4.9422 .6989
50 15.436 4.3863 .6203
50 36.132 14.2593 2.0166
50 36.418 9.4658 1.3387
50 10.710 2.5453 .3600
50 11.138 2.5136 .3555
50 5588.00 3241.670 458.441
50 6850.00 4321.623 611.170
GROUP
1
2
1
2
1
2
1
2
1
2
1
2
ALB
GLO
PT
APTT
HB
TC
N Mean Std. Deviation
Std. Error
Mean
   
ALB= Albumin, GLO=Globulin, PT=Prothrombin time, HB= Hemoglobin 
aPTT= activated  partial  thromboplatin time, TC= Total count. 
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Table-12                       
Independent Samples Test
.815 98 .417 .136 .1668 -.1950 .4670
.815 97.738 .417 .136 .1668 -.1950 .4670
1.265 98 .209 .224 .1771 -.1275 .5755
1.265 96.794 .209 .224 .1771 -.1275 .5755
-.987 98 .326 -.922 .9345 -2.7765 .9325
-.987 96.637 .326 -.922 .9345 -2.7768 .9328
-.118 98 .906 -.286 2.4204 -5.0893 4.5173
-.118 85.163 .906 -.286 2.4204 -5.0984 4.5264
-.846 98 .400 -.428 .5059 -1.4319 .5759
-.846 97.985 .400 -.428 .5059 -1.4319 .5759
-1.652 98 .102 -1262.00 764.001 -2778.135 254.135
-1.652 90.881 .102 -1262.00 764.001 -2779.620 255.620
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
ALB
GLO
PT
APTT
HB
TC
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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Mann-Whitney Test: 
Table-13 
Ranks
50 49.81 2490.50
50 51.19 2559.50
100
50 47.41 2370.50
50 53.59 2679.50
100
50 49.90 2495.00
50 51.10 2555.00
100
50 48.43 2421.50
50 52.57 2628.50
100
50 48.15 2407.50
50 52.85 2642.50
100
50 54.30 2715.00
50 46.70 2335.00
100
50 48.01 2400.50
50 52.99 2649.50
100
50 45.86 2293.00
50 55.14 2757.00
100
50 56.95 2847.50
50 44.05 2202.50
100
50 52.87 2643.50
50 48.13 2406.50
100
GROUP
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
MELD
TB
DB
SGOT
SGPT
ALP
PLATELETHB
TC
ESR
SGOT/SGPT
N Mean Rank Sum of Ranks
 
MELD= model for end-stage liver disease, TB= Total bilirubin , DB= Direct 
bilirubin ALP= Alkaline phosphatase  
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Table-14 
Test Statistics
1215.500 1095.500 1220.000 1146.500 1132.500
2490.500 2370.500 2495.000 2421.500 2407.500
-.238 -1.066 -.208 -.714 -.810
.811 .286 .835 .475 .418
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed
MELD TB DB SGOT SGPT
 
Table-15 
Test Statisticsa
1060.000 1125.500 1018.000 927.500 1131.500
2335.000 2400.500 2293.000 2202.500 2406.500
-1.310 -.858 -1.600 -2.239 -.817
.190 .391 .110 .025 .414
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
ALP PLATELETHB TC ESR SGOT/SGPT
Grouping Variable: GROUPa. 
 
For all non normally distributed data a Mann whitney test was done for the 
above investigation and laboratory  parameters including MELD  scores    to see 
if there is any statistically significant difference between the groups  and was 
found to be significant  only ESR at P<0.05. 
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Model   for  end-stage liver disease (MELD): 
There was no difference in the MELD score between the cases and controls. 
Table -16 
 MELD 
Mann-Whitney U 
Wilcoxon W 
Z 
Assymp. Sig.(2-tale) 
1215.502 
490.500 
-.238 
.811 
 
  (  Also ref. to table-14) 
Below is the frequency data (ref. Table-17) 
 MELD score frequency   data ( cases and control): 
Table-17 
MELD 
Score 
Cases (No.  of 
patients) 
Controls(No. of 
patients) 
1-5 12 15 
6-10 19 15 
11-15 16 14 
16-22 03 06 
 Total =50 Total =50 
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Comparison of MELD score  in relation to  histological liver injury:   
When the MELD score was below 6, there were very few cases with 
severe injury.  When MELD scores were above   6 , the histological damage  was 
much more but did not show a progressive increase thereafter (ref. table-18). 
Table-18  
 MELD SCORES 
NASH 1-5 6-10 11-15 16-20 
Mild 07(58.34%) 02(10.53%) 04(25.00%) 00(0.00%) 
Moderate 04(33.34%) 06(31.58%) 05(31.58%) 01(33.33%) 
Severe 01(08.34%) 11(57.89%) 07(43.75%) 02(66.33%) 
 
Distribution of histological severity of the disease according to the MELD score  
 
13
16
21
Mild Moderate Severe
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Graph: Comparision of histologic grades ( NASH) with  MELD score.  
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Conclusion 
1) This study used cases and controls with similar MELD scores, gender   
ratios  and age ranges. Therefore these are   fairly well matched   cases 
and controls.  
2) In this study of chronic liver disease with steatohepatitis, we found that  
group-2 (diseased controls) were  more likely to have Jaundice,    ascites   
and   gastrointestinal bleeding. The cases were more likely to have pedal 
edema.These differences were statistically significant.  
3) All investigational parameters between the two groups were not 
significantly different except for the ESR.  
4) MELD score showed no correlation with histological findings in the 
Steatohepatitis cases it was observed that with MELD scores below 6 
there were few patients with severe histological damage. However the 
damage did not proportionately increase above 6.  
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Part - II 
Title :  Serum  Anti-Mitochondrial  Antibody  (AMA)  in Cryptogenic Chronic  Liver  
disease  with  elevated Serum  Alkaline Phosphatase   levels. 
AIM 
• To determine  how  frequently  the Anti mitochondrial antibody test  is      
positive  in patients with chronic liver disease with high serum alkaline      
phosphatase levels.  
• To identify the discriminatory value of clinical features in patients who 
tested   positive for AMA from those with a negative test. 
Material and Methods 
Study design: Retrospective   case-control study. 
Study population and sample size: 
This was a retrospective study  where 120 patients  with chronic liver 
disease for whom the anti mitochondrial test (AMA) was done because of a 
raised alkaline phosphatase (ALP) either at presentation or on initial follow up 
formed the population from  which cases and controls were drawn. 10 patients 
who tested AMA positive (and this   was the entire AMA positive group of the 120 
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cases) served as cases and 20 subjects   that were randomly chosen from the 
AMA negative group served as controls.  
In order to do this we used the following method of identifying the total 
AMA positive population.The records of the serological laboratory between 
January 2004 and February 2005 were scrutinized and all those for whom an 
AMA test was requested were chosen for inclusion.   All of these had chronic 
liver disease with an elevated serum alkaline phosphates level.   
All subjects who tested positive for the AMA were included as cases. Of 
those in this population who had elevated alkaline phosphatase but tested 
negative for AMA a   sample of subjects was drawn to act as controls.  
This was random but was intentionally skewed towards the female gender 
to match the gender ratio of the cases.   A random selection of 20  test negative  
controls was heavily  skewed  towards  the male  sex.   Therefore a  selection  of  
2  males  and 18 females  were made randomly from  gender  separate  groups. 
      The next stage was examining the records and investigations of both 
these groups at admission.  The following steps were undertaken. 
1) The clinical findings and investigational reports of the cases were 
compared with those in the controls to look for any significant differences. 
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2)  The clinical findings on presentation that were recorded for the study 
were the presence of jaundice, ascites and pedal oedema. Other clinical 
findings were not included in the comparative analysis. Encephalopathy 
and spontaneous bacterial peritonitis was recorded if it was the reason for 
admission. A past history of either was disregarded.  
3) Among the investigations, the indices of liver function, haematological 
parameters such as haemoglobin and platelets, ESR and Anti nuclear 
antibody (if available) were compared in the two groups. Further the ratio 
such as SGOT/SGPT was also compared. Other investigations such as 
imaging and endoscopy were not included in the study          
Statistical Methods: 
Descriptive statistics like mean and SD were presented for normally 
distributed continuous variables and median with interquartile  range for non-
normally distributed continuous variables.  The results between the two groups 
were compared for statistically significant difference.   For the categorical 
variables chi-square test was used. For continuous variable with normal 
distribution, t- test was used. For continuous variable with non-normal 
distribution, Mann-Whitney’s U test was used.   P value of   <0.05 was 
considered significant. The statistical analysis was done using SPSS software for 
windows version 16. 
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Results 
AMA was requested for 120 patients during the period between January 
2004 to January 2005.  Out of total 120 patients 95 were females and 25 were 
males.    
The age range was between 18-70Years   (Mean ± SD=43.63 ± 13.11) 
Only 10 patients were   tested positive for AMA and rest were negative.   In the 
Positive group were nine Females and one Male; age ranges from 18 – 70 years 
(Mean ± SD=43.8 ± 13.63). 
Alkaline Phosphatase levels: 
The range of  ALP levels  for  all 120  cases was  56 to 1266 IU/L  with  
mean ± SD=303.83 ±267.34IU/L;  ALP value  for  AMA  positive cases(n=10)  
range  132  -1266 IU/L with a medial value =267.50 IU/L and a  mean ± 
SD=368.40 ± 340.08  IU/L. ALP for   Controls  group (n=20)   range from  133 to 
853IU/Lwith  a median value =204.50 IU/L and  mean ± SD = 294.06 ± 189.78). 
Characteristics of patients:     
There were no significant differences   in age,   sex and   MELD score 
between AMA positive and AMA negative groups.   
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(Table-19) 
Characteristics of patients.
ns7-118-10MELD
nsM=2/F=18M=1/F=9Sex 
ns18-62
(Mean=42.7)
18-70  
(Mean=38) 
Age in 
years.
-N=20N=10No of 
patients.
P  valueControl  group
AMA (- )
Study group
AMA(+)
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CLINICAL FEATURES: 
ASCITES: 4(40%) patients in group -1   and 10(50%) patients in group -11   were 
having ascites , rest  were  negative both clinically  and  radiologically.  
Table- 20 
ASCITES Yes No Total 
Group -1(AMA+) 4(40%) 6(60%) 10(100%) 
Group-2(AMA-) 10(50%) 10(50%) 20(100%) 
     
 
Ascites: 
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JAUNDICE: 2(20%) patients from gr-1 and 7(35%) from gr-11 were   having                    
Jaundice,  this  was not   statistically significant .   
Table-21 
Jaundice Yes No Total 
Group-1(AMA+) 2(20%) 9(90%) 10(100%) 
Group-2(AMA-) 7(35%) 13(65%) 20(100%) 
 
Jaundice: 
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EDEMA: Pedal edema was seen in 2(20%) patients in gr-1 and 8(40%)            
patients  in gr-2, this was not  statistically significant.   
Table-22    
Edema Yes No Total 
Group-1(AMA+) 2(20%) 08(80%) 10(100%) 
Group-2(AMA-) 8(40%) 12(60%) 20(100%) 
 
Edema: 
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COMPLICATIONS: 
Spontaneous bacterial peritonitis:  There were 1(10%) in gr-1 & 2(10%) in gr-
11 having SBP, this was not statistically significant. 
Table-23 
SBP Yes No Total 
Group-1(AMA+) 1(10%) 9(90%) 10(100%) 
Group-2(AMA-) 2(10%) 18(90%) 20(100%) 
 
 
SBP: 
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  Hepatic encephalopathy: 1(10%)   patient   from group-1 and 1(05%) patient                          
from group-2 developed hepatic encephalopathy, this was not statistically 
significant. 
Table-24    
HE Yes No Total 
Group-1(AMA+) 1(10%) 9(90%) 10(100%) 
Group-2(AMA-) 1(05%) 19(95%) 20(100%) 
 
Hepatic encephalopathy: 
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BLEED: There was 1(05%) patient who had esophageal variceal bleed in gr-2 
but there was no episode of  bleed in gr-1, this was not  statistically        
significant. 
Table-25 
Bleed Yes No Total 
Group-1(AMA+) 0 10(100%) 10(100%) 
Group-2(AMA-) 1(05%) 19(95%) 20(100%) 
 
Bleed: 
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Composite   Table-20-25 
Indices AMA positive AMA negative s/s[p<0.05] 
Ascites 4(40%) 10(50%) ns 
Jaundice 2(20%) 7(35%) ns 
Edema 2(20%) 8(40%) ns 
SBP 1(10%) 2(10%) ns 
HE 1(10%) 2(10%) ns 
Bleed 0 1(10%) ns 
 
  s/s=statistically   significant, ns= not significant SBP=spontaneous bacterial 
peritonitis, HE= hepatic encephalopathy. 
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Investigation and Laboratory parameters: 
The two groups did not show significant difference for most of the                          
parameters except TB and aPTT (ref. Table-21). 
Table-26 
 
Group-1(AMA+) Group-2(AMA-) Mean differ. 
Mean ± SD Mean ± SD  
TB 2.3 3.4 5.555 7.8 3.255  ** 
DB 1.18 2.13 3.525 5.945 2.345 
Alb: 
Glo: 
3.33 
4.31 
0.636 
0.735 
3.135 
3.83 
0.701 
1.128 
-0.205 
-0.28 
SGOT 97.6 65.501 168.4 278.683 70.8 
SGPT 75.8 55.838 135 314.547 59.2 
ALP 360.4 346.176 265.55 210.654 -94.85 
PT 12.63 5.81 13.56 2.08 0.93 
aPTT 23.16 16.366 35.87 5.648 12.71 ** 
 
**   significant at P<0.05 
TB= Total bilirubin, DB=Direct bilirubin,Alb= albumin, Glo=globulin, 
ALP=alkaline phosphatase, PT= prothronbin time, aPTT= activated partial 
thromboplastin time.  
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Independent samples  t-Test: 
Table-27 
Parameters Groups(AMA+And AMA- ) N Mean SD t-Value df 
ALB 1 2 
10 
20 
3.38 
3.14 
0.561 
0.701 
0.959 
1.034 
0.346 
0.312 
GLOBULIN 1 2 
10 
20 
4.310 
4.255 
0.7355 
1.2344 
0.128 
0.152 
0.899 
0.881 
PT 1 2 
10 
20 
12.630 
13.560 
5.8071 
2.0775 
-0.647 
-0491 
0.532 
0.634 
HB 1 2 
10 
20 
10.410 
11.060 
2.1605 
2.2369 
-0.759 
-0.768 
0.454 
0.452 
TC 1 2 
10 
20 
6480 
7360 
2766.386
3437.778
-0.702 
-0.756 
0.489 
0.458 
SGOT/SGPT 1 2 
10 
20 
1.3962 
1.5176 
0.47843 
0.61377 
-O.546 
-0.594 
0.589 
0.558 
 
HB= hemoglobin, TC= Total count 
Table-28 
Test Statisticsb
73.500 54.000 62.000 100.000 95.500 80.000 49.000 99.000
128.500 109.000 117.000 310.000 305.500 290.000 104.000 154.000
-1.170 -2.028 -1.680 .000 -.198 -.880 -2.245 -.044
.242 .043 .093 1.000 .843 .379 .025 .965
.248
a
.044
a
.100
a
1.000
a
.846
a
.397
a
.024
a
.983
a
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed
Exact Sig. [2*(1-taile
Sig.)]
MELD TB DB SGOT SGPT ALP APTT PLATELATE
Not corrected for ties.a. 
Grouping Variable: GROUPb. 
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For all non normally distributed data a Mann Whitney test was done for the 
various parameter to see if there is any statistically significant difference between 
the gps and was found to be significant only for TB and APTT at P<0.05. 
Other features: 
ANA: ANA were positive 50% in both the groups, there was no significant 
statistically. 
ANA POSITIVITY 
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Liver biopsy and histology: 
Liver biopsy were available on 3 out of 10 AMA positive and on 11 out of 
20 AMA negative patients.  The   rest did not undergo liver biopsy.  In the AMA 
positive group, none of them had characteristics of Primary biliary cirrhosis. 
In AMA   negative patients, biopsy findings were similar ;  however  one 
patient had  features suggestive of  primary biliary cirrhosis  and another had 
granulomas  on histology (ref. table-22 &23).  
Comparison of USG abdomen and  liver histology between the AMA 
positive and AMA negative groups(table 29&30): 
Table -29       
USG/ Liver Bx
AMA- (n=20)AMA+(n=10)
Chronic cholestasis.6)Early CLD-6)Coarse
Focal portal 
inflammation 
&fibrosis
5) Coarse &vr+-5)Coarse & lobulated
-4) Coarse &vr+Bridging fibrosis, 
nudularity &focal 
bile duct damage
4)Coarse
Moderate periportal
inflammation with 
periportal & bridging 
fibrosis
3)Mildly Coarse & 
enlarged
Sinusoidal 
congestion& 
pericellular
fibrosis
3)Coarse&lobulatd
Micronodular
cirrhosis
2)Coarse-2)Irregular&surfae nodularity
-1)Coarse&vr+-1)Coarse,Shrunken& vr+
Liver bxUSG abdo.Liver bxUSG abdo.
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Table – 29 contd.. 
AMA-(n=20)AMA+ (n=10)
Cirrhosis with focal 
activity.
12) Shrunken, 
coarse
-11) Coarse &irregular margin
-10)Coarse &nodular10)Shrunken,
coarse& 
nodular
-9) Early CLD9) early focal bridging 
fibrosis&moderate
periportal inflammation.
9)Coarse
Granulomatous
inflammation with 
periportal bridging 
fibrosis
8) Coarse &vr+-8)vr+, coarse &nodular
-7)Nodular& vr+-7)Coarse , nodular & vr+
Liver bxUSG abdo.Liver bxUSG abdo.
 
Table-30 
     USG / liver biopsy  in AMA – ve patients: 
USG  abdomen 
 Liver bx 
13)Shrunken coarse& Micronodular 
cirrhosis 
 
Micronodular  cirrhosis 
14)Coarse & irregular surface 
 
Portal inflammation with destruction 
&disappearance  intrahepatic bile ducts 
, abnormal  bile duct proliferation, 
fibrosis & cirrhosis and f/s/o primary 
biliary cirrhosis. 
15) Coarse & irregular surface 
 Cirrhosis with mild steatosis 
16) Coarse & irregular surface 
 - 
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17)Diffusely Coarsing  & irregular 
surface 
 
Bridging  fibrosis with nodularity  & mild 
inflammation 
18)Coarse & irregular surface 
 - 
19) Coarse & shrunken 
 
Early focal bridging fibrosis & moderate 
periportal  inflammation 
20) Coarse & shrunken 
 - 
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Conclusion 
1) AMA was rarely positive (about 8.33%) in this group of cryptogenic chronic 
liver disease with high ALP values.    
2) The clinical picture and investigational results were not different from AMA 
negative controls. 
3) The only discriminating investigations are a high Total Bilirubin, and 
activated Partial Thromboplastin Time in cases which are AMA positive.   
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Discussion 
Cryptogenic liver disease in the late stages is often overlooked because 
the condition requires transplantation and this mode of therapy is widely available 
in the West.   However this is not always possible in poorer societies. There are 
new treatments that are emerging which may rescue people with advanced 
disease.  The best example is the success that new therapies have had in such 
conditions such as HBV infection.  It is possible that in the  future  we may 
similarly be able to treat other  conditions in late stages without resorting to liver 
transplantation.  
It is therefore important to study patients who are passed off as 
cryptogenic disease only on the grounds that the serological markers of viral 
infection and a history of alcohol abuse is absent. We chose two groups from 
such a population of patients. 
The first was steatohepatitis. This was possible because of fortuitous 
availability of liver biopsy material. The second was those with high alkaline 
phosphatase levels to examine if the AMA test could be used to detect PBC in 
this group. It was also hoped that the clinical picture, or investigational results 
would help in making a diagnosis of NASH and/or PBC before a biopsy or test is 
conducted. 
There are many possible causes for cryptogenic liver disease.   We have 
looked at only  two groups: a) those which had biopsy evidence of 
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Steatohepatitis and b) those with  high alkaline phophatase or putative PBC. 
There are possibly many other causes.  These would include cryptogenic 
autoimmune liver disease for which there is no reliable autoimmune marker. It 
may also include occult HBV infection or copper storage disorders. It could also 
be non cirrhotic liver disease which presents with the syndrome of chronic liver 
failure. The problem is that in many of these conditions, the liver disease is so 
advanced that the signs of the original cause may have disappeared. This 
scenario is the accepted opinion in NASH. 
The findings of this retrospective study on patients histologically proven to 
have advanced NASH has demonstrated that among this population with non 
viral, non alcoholic cryptogenic disease are a number of cases of steatohepatitis. 
In the period of three years there were 50 cases.  This is an underestimation as 
there were many who did not undergo a liver biopsy as they were either too 
advanced or for other reasons. Further as the steatosis disappears with 
advancing disease a number may  have escaped detection. 
The first question was whether clinical or laboratory parameters would 
help arrive at a diagnosis. Although there were significant differences in the 
number of cases with jaundice, ascites, gastrointestinal bleeding and peripheral 
oedema between patients and controls, none of these can be used alone or 
together to make a clinical diagnosis of advanced NASH. Among the laboratory 
tests the ESR was different.  This is found surprisingly higher in the NASH group 
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rather than controls.  Again this cannot be used for the diagnosis of the condition.   
However it may point to the fact that there is ongoing inflammation.             
The clinical findings of more ascites and gastrointestinal bleeding in the 
control group - while the pedal oedema is higher in NASH - is a strong 
suggestion that portal   hypertension is lower in the group with NASH. This 
seems particularly relevant as the MELD scores and serum albumin levels were 
not different in the two groups.  
         It appears from the above finding that in the NASH group, hypo-
albuminemia is the cause of pedal edema.  In the control group the low albumin 
combined with a high hydrostatic portal pressure results in Gastro Intestinal 
bleeds and ascites.  This requires confirmation by wedged hepatic pressure.  The 
difference in the number of patients with Jaundice is unexplained but may point 
to other protective mechanisms.   
With regard to the second question about correlation between the 
histological severity and the MELD scores, it was found that although there was a 
trend to higher MELD scores with increasing severity , this seemed to level off 
after a MELD score of 6.Therefore MELD scores could not be used to predict the 
nature of the histological damage.  What are the implications of these findings? A 
liver biopsy is essential for the diagnosis of NASH in advanced disease. There is 
a need to study the nature of portal hypertension in patients with NASH.   
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The studies on those with high Alkaline phosphatase levels showed that 
the AMA test was very rarely positive. The majority of patients who tested 
positive were women who also were positive for the ANA test.  Therefore the 
conclusion that can be drawn is   that PBC is either a rare disease or that it is 
falsely negative in many of our patients.  
This has to be proven by other means such as by examining histology in 
this group.  The group who tested positive for AMA was not different from those 
that were negative either on the basis of clinical or investigational findings, which 
makes a case for a large population of occult PBC in this population. 
These studies make a case for liver biopsies in advanced liver disease. 
This and other investigations and studies in cryptogenic liver disease may 
prepare us for the therapies that may appear in the future.   
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Final Conclusion 
1) Patients with advanced NASH cannot be clinically distinguished from 
patients with   other chronic liver disdease . Therefore biopsy is essential. 
2) Patients with steatohepatitis have less chance of developing ascites and   
having a gastrointestinal hemorrhage.  
3) They have a lesser chance of gastro intestinal bleeds and edema.  This 
may  reflect   differences in portal hypertension  
4) There was no  histological correlation   with MELD scores.    
5) AMA is rarely positive (about 8.33%) in cryptogenic   chronic liver disease 
with high   ALP   values. 
6) The clinical picture is not different from that of AMA negative controls.  
7) The only discriminating investigations are a high Total Bilirubin, and 
activated Partial Thromboplastin Time in cases with AMA positive. 
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Investigations 
1. CBC profile, ESR, ANA 
2. Serum biochemistry 
3. virological study 
4. Imagings 
         U/S Abdomen,  
5. Per cut. / TJLB liver biopsy 
6. Histologic examination 
         Dry weight copper and special stains as clinical situation. 
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Appendix -1 – master  sheet 
Abbreviations 
M= Male 
F= Female 
HB= Hemoglobin (g%) 
TC=Total count  
ESR in mm/hr 
ALB= Albuminin  g% 
SBP= spontaneous  bacterial peritonitis 
HE= Hepatic encephalopathy, CC=cryptogenic cirrhosis 
MELD= Model for End stage Liver Disease  
TB= Total bilirubin 
DB= Direct  bilirubin  
GLO= Globulin 
 71
SGOT=serum glutamic –oxaloacetic  transaminase  
SGPT=Serum glutamic-pyruvic   transaminase 
ALP=Alkaline phosphatase 
PT=Prothrombin time 
aPTT =Activated  prothrombin time 
ANA=antinueclear anti body 
Male-1, Female-2 
Ascites present-1, abscent-2 
SBP present-1, abscent-2 
HE present-1, abscent-2 
Jaundice present-1, abscent-2 
Bleed present-1, abscent-2 
Edema present-1, abscent-2:  ANA (+)=1,(-)=2 
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Appendix-2 (NASH SCORING) 
 [University Pathologists - Staging and Grading – Liver] 
NONALCOHOLIC STEATOHEPATITIS STAGING 
Stage Histologic criteria 
1 Zone 3 perivenular perisinusoidal/pericellular fibrosis, focal or extensive 
2 As above with focal or extensive periportal fibrosis 
3 Bridging fibrosis, focal or extensive 
4 Cirrhosis 
 
REFERENCE 
Brunt EM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging 
the histologic lesions. Am J Gastroenterol 1999;94;2467-74. 
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NASH STAGING AND GRADING - Nonalcoholic Steatohepatitis Clinical 
Research Network scoring system (Nonalcoholic Steatohepatitis Activity Score - 
NAS), 2005 
ACTIVITY SCORE 
Histologic feature Grade Description 
Steatosis 
  
  
  
0 <5% 
1 5-33% 
2 33-66% 
3 >66% 
Lobular inflammation 
  
  
  
0 None 
1 <2 foci/200x field 
2 2-4 foci/200x field 
3 >4 foci/200x field 
Ballooning 
  
  
0 None 
1 Few balloon cells 
2 Many cells/ prominent ballooning
 
NAS > 5 = NASH, NAS<2 = no evidence of NASH, NAS 3-4 = borderline/possible  
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FIBROSIS STAGING 
Stage Histologic criteria 
1 
Zone 3 perivenular perisinusoidal/pericellular fibrosis, 
focal or extensive
· 1A - delicate perisinusoidal fibrosis
· 1B - dense perisinusoidal fibrosis
· 1C - portal-only fibrosis 
2 As above with focal or extensive periportal fibrosis 
3 Bridging fibrosis, focal or extensive 
4 Cirrhosis 
 
REFERENCE: Kleiner DE, et al. Design and validation of histologic scoring 
system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. 
                                                                                                                      
 
